Fig 2: (A,B) Overall survival and (C,D) disease-free survival rates according to SERPINE2 immunoreactivity in both upper tract and bladder urothelial carcinoma.

Fig 3: Representative sections of the normal urothelium (A), low-grade urothelial carcinoma (UC) (B), and high-grade UC (C,D) stained with H&E and immunostained for SERPINE2 (E–H). SERPINE2 immunoreactivity to the normal urothelium, low-grade UC, and high-grade UC was observed as (E) negative, (F) weak (1+), (G) moderate (2+), and (H) strong (3+). Scale bar in (A), 100 µm. The scale bar applies to all panels.

Fig 4: SERPINE2 was upregulated in urothelial carcinoma tissues. Quantification of SERPINE2 immunoexpression in 75 paired urothelial carcinoma specimens and significance determined by the paired t-test. ***, p < 0.001.